 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|||||||||||||
|
[ back to News ] Concert Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference on September 16, 2010 |
|||||||||||||||
Lexington, MA –– Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the 2010 Stifel Nicolaus Healthcare Conference on Thursday, September 16, 2010 at 10:55 a.m. ET. The conference will be held September 15-17, 2010 at the Four Seasons Hotel in Boston, Massachusetts.
About Concert
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ to create novel and differentiated small molecule drugs containing deuterium. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.
[ back to top ]
|
|
|
|
|
| ©2009 Concert Pharmaceuticals, Inc. Design by Digizyme |
||||
|
|
|
|
|